|
π’
|
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.
14 auth.
B. Lannutti,
S. A. Meadows,
S. E. Herman,
A. Kashishian,
B. Steiner,
A. Johnson,
J. Byrd,
J. Tyner,
M. Loriaux,
M. Deininger,
...
B. Druker,
K. Puri,
R. Ulrich,
N. Giese
|
9 |
2011 |
9
π’
|
|
π¬
|
Coβlocalization of NG2 proteoglycan and PDGF Ξ±βreceptor on O2A progenitor cells in the developing rat brain
A. Nishiyama,
X.βH. Lin,
N. Giese,
C. Heldin,
W. Stallcup
|
9 |
1996 |
9
π¬
|
|
π
|
Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
15 auth.
S. E. Herman,
Amber L. Gordon,
Amy J. Wagner,
N. Heerema,
Weiqiang Zhao,
J. Flynn,
Jeffrey A Jones,
L. Andritsos,
K. Puri,
B. Lannutti,
...
N. Giese,
Xiaoli Zhang,
Lai Wei,
J. Byrd,
A. Johnson
|
9 |
2010 |
9
π
|
|
π
|
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
12 auth.
Julia Hoellenriegel,
S. A. Meadows,
M. Sivina,
W. Wierda,
H. Kantarjian,
M. Keating,
...
N. Giese,
S. OβBrien,
A. Yu,
L. Miller,
B. Lannutti,
J. Burger
|
9 |
2011 |
9
π
|
|
π’
|
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
N. Lokker,
Carol M. Sullivan,
S. Hollenbach,
M. Israel,
N. Giese
|
8 |
2002 |
8
π’
|
|
π
|
PDGF-D, a new protease-activated growth factor
18 auth.
W. Larochelle,
M. Jeffers,
W. McDonald,
R. Chillakuru,
N. Giese,
N. Lokker,
Carol M. Sullivan,
F. Boldog,
Meijia Yang,
C. Vernet,
...
C. Burgess,
E. Fernandes,
Lisa L. Deegler,
B. Rittman,
Juliette Shimkets,
R. Shimkets,
J. Rothberg,
H. Lichenstein
|
8 |
2001 |
8
π
|
|
π’
|
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).
22 auth.
Louise M. Kelly,
Louise M. Kelly,
Jin-Chen Yu,
Christina L. Boulton,
Mutiah Apatira,
Jason Li,
Carol M. Sullivan,
I. Williams,
Sonia M Amaral,
Sonia M Amaral,
...
D. Curley,
Nicole Duclos,
Nicole Duclos,
D. Neuberg,
R. M. Scarborough,
A. Pandey,
S. Hollenbach,
K. Abe,
N. Lokker,
D. Gilliland,
D. Gilliland,
N. Giese
|
8 |
2002 |
8
π’
|
|
π¬
|
Interaction between NG2 proteoglycan and PDGF Ξ±βreceptor on O2A progenitor cells is required for optimal response to PDGF
A. Nishiyama,
X.βH. Lin,
N. Giese,
C. Heldin,
W. Stallcup
|
7 |
1996 |
7
π¬
|
|
π
|
Block of C/EBPΞ± function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations
17 auth.
H. Radomska,
D. S. Bassères,
R. Zheng,
Pu Zhang,
Tajhal Dayaram,
Yukiya Yamamoto,
D. Sternberg,
N. Lokker,
N. Giese,
S. Bohlander,
...
S. Schnittger,
M. Delmotte,
R. Davis,
D. Small,
W. Hiddemann,
D. Gilliland,
D. Tenen
|
7 |
2006 |
7
π
|
|
π
|
PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
20 auth.
H. Ikeda,
T. Hideshima,
M. Fulciniti,
G. Perrone,
N. Miura,
H. Yasui,
Y. Okawa,
T. Kiziltepe,
L. Santo,
S. Vallet,
...
D. Cristea,
E. Calabrese,
G. Gorgun,
N. Raje,
P. Richardson,
N. Munshi,
B. Lannutti,
K. Puri,
N. Giese,
K. Anderson
|
7 |
2010 |
7
π
|
|
π
|
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
7 auth.
J. Rocnik,
R. Okabe,
Jin-Chen Yu,
Benjamin H. Lee,
N. Giese,
D. Schenkein,
...
D. Gilliland
|
7 |
2006 |
7
π
|
|
π
|
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
11 auth.
A. Pandey,
D. Volkots,
J. Seroogy,
J. Rose,
Jin-Chen Yu,
J. Lambing,
...
A. Hutchaleelaha,
S. Hollenbach,
K. Abe,
N. Giese,
R. Scarborough
|
6 |
2002 |
6
π
|
